Cellectis S.A. の製品パイプライン分析2016

【英語タイトル】Cellectis S.A. - Product Pipeline Review - 2016

Global Markets Directが出版した調査資料(DATA70209157)・商品コード:DATA70209157
・発行会社(調査会社):Global Markets Direct
・発行日:2016年10月19日
・ページ数:25
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥160,500見積依頼/購入/質問フォーム
Site LicenseUSD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD4,500 ⇒換算¥481,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Cellectis S.A. – Product Pipeline Review – 2016
Summary

Global Markets Direct’s, ‘Cellectis S.A. – Product Pipeline Review – 2016’, provides an overview of the Cellectis S.A.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Cellectis S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Cellectis S.A.
- The report provides overview of Cellectis S.A. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Cellectis S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Cellectis S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Cellectis S.A.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cellectis S.A.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cellectis S.A.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Cellectis S.A. Snapshot 4
Cellectis S.A. Overview 4
Key Facts 4
Cellectis S.A. – Research and Development Overview 5
Key Therapeutic Areas 5
Cellectis S.A. – Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products – Monotherapy 8
Pipeline Products – Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
Pipeline Products – Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Cellectis S.A. – Pipeline Products Glance 13
Cellectis S.A. – Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Cellectis S.A. – Drug Profiles 14
UCART-123 – Drug Profile 14
Product Description 14
Mechanism Of Action 14
R&D Progress 14
UCART-22 – Drug Profile 16
Product Description 16
Mechanism Of Action 16
R&D Progress 16
UCART-38 – Drug Profile 17
Product Description 17
Mechanism Of Action 17
R&D Progress 17
UCARTCS-1 – Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
Cellectis S.A. – Pipeline Analysis 19
Cellectis S.A. – Pipeline Products by Target 19
Cellectis S.A. – Pipeline Products by Molecule Type 20
Cellectis S.A. – Pipeline Products by Mechanism of Action 21
Cellectis S.A. – Dormant Projects 22
Cellectis S.A. – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 24
Disclaimer 25

List of Tables
Cellectis S.A., Key Facts 4
Cellectis S.A. - Pipeline by Indication, 2016 6
Cellectis S.A. - Pipeline by Stage of Development, 2016 7
Cellectis S.A. - Monotherapy Products in Pipeline, 2016 8
Cellectis S.A. - Partnered Products in Pipeline, 2016 9
Cellectis S.A. - Partnered Products/ Combination Treatment Modalities, 2016 10
Cellectis S.A. - Out-Licensed Products in Pipeline, 2016 11
Cellectis S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016 12
Cellectis S.A. - Preclinical, 2016 13
Cellectis S.A. - Pipeline by Target, 2016 19
Cellectis S.A. - Pipeline by Molecule Type, 2016 20
Cellectis S.A. - Pipeline Products by Mechanism of Action, 2016 21
Cellectis S.A. - Dormant Developmental Projects,2016 22
Cellectis S.A., Subsidiaries 23

List of Figures
Cellectis S.A. - Pipeline by Indication, 2016 6
Cellectis S.A. - Out-Licensed Products in Pipeline, 2016 11
Cellectis S.A. - Pipeline by Target, 2016 19
Cellectis S.A. - Pipeline Products by Mechanism of Action, 2016 21

★調査レポート[Cellectis S.A. の製品パイプライン分析2016] (コード:DATA70209157)販売に関する免責事項を必ずご確認ください。
★調査レポート[Cellectis S.A. の製品パイプライン分析2016]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆